Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Beilu Pharmaceutical Co., Ltd (300016.SZ)
CNY8.60
+0.35 (+4.24%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Maples International Office 100082
Beijing, CN
Beijing, CN
CEO
Xu Wang
Website
beilu.com.cn
IPO
2009-10-30
ISIN CNE000001QK9
Description
Beijing Beilu Pharmaceutical Co., Ltd., established in 1992 and headquartered in Beijing, China, operates within the pharmaceutical industry. The company is primarily involved in the research, development, production, and commercialization of diverse medicinal products. Its offerings notably include specialized drugs like contrast agents, treatments for central nervous system conditions, and oral medications designed for diabetes. Additionally, Beilu Pharmaceutical also ventures into the manufacturing of precision medicine.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY8.60
+0.35 (+4.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
19M
Beta
0.29
Float Shares
546.00M
Free Float %
93.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.20% | -5.53% | -13.41% | -20.62% | -1.09% | +3.27% | +17.65% | +7.89% | -15.81% | -37.97% | +55.60% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8.60
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.10
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+21.7% ★ Q1'26: +13.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+500.0% ★ Q1'26: +170.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1.6% Q1'26: +23.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.6% Q1'26: +15.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.8% Q1'26: +7.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+13.2% Q1'26: +14.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.34× ★ Q1'26: 3.34× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
491.43M
est: 563.00M (-12.7%)
|
498.86M
est: 499.00M (0.0%)
|
522.54M
est: 565.00M (-7.5%)
|
608.05M
est: 613.00M (-0.8%)
|
819.12M
est: 799.00M (+2.5%)
|
827.34M
est: 1.01B (-18.4%)
|
1.18B
est.
|
859.91M
est: 1.45B (-40.8%)
|
890.72M
est: 869.00M (+2.5%)
|
765.88M
est: 869.00M (-11.9%)
|
983.55M
est: 1.08B (-8.6%)
|
1.20B
est: 1.40B (-14.3%)
|
1.66B
1.66B – 1.66B
+18.9% YoY
|
| EBITDA |
71.60M
est: 99.68M (-28.2%)
|
43.13M
est: 88.35M (-51.2%)
|
157.97M
est: 100.04M (+57.9%)
|
184.78M
est: 108.54M (+70.2%)
|
417.52M
est: 141.47M (+195.1%)
|
221.38M
est: 179.54M (+23.3%)
|
208.93M
est.
|
230.96M
est: 257.27M (-10.2%)
|
33.26M
est: 153.86M (-78.4%)
|
109.49M
est: 153.86M (-28.8%)
|
147.90M
est: 161.62M (-8.5%)
|
181.74M
est: 209.84M (-13.4%)
|
249.49M
249.49M – 249.49M
+18.9% YoY
|
| EBIT |
51.85M
est: 51.78M (+0.1%)
|
22.92M
est: 45.89M (-50.1%)
|
140.56M
est: 51.96M (+170.5%)
|
167.22M
est: 56.38M (+196.6%)
|
396.90M
est: 73.48M (+440.1%)
|
178.68M
est: 93.26M (+91.6%)
|
108.53M
est.
|
168.26M
est: 133.63M (+25.9%)
|
-48.02M
est: 79.92M (-160.1%)
|
34.56M
est: 79.92M (-56.8%)
|
57.68M
est: 67.05M (-14.0%)
|
79.08M
est: 87.06M (-9.2%)
|
103.51M
103.51M – 103.51M
+18.9% YoY
|
| Net Income |
32.58M
est: 111.51M (-70.8%)
|
16.38M
est: 16.40M (-0.1%)
|
118.82M
est: 121.35M (-2.1%)
|
147.76M
est: 137.75M (+7.3%)
|
342.44M
est: 186.94M (+83.2%)
|
174.70M
est: 206.62M (-15.4%)
|
226.30M
est.
|
125.51M
est: 280.41M (-55.2%)
|
-71.76M
est: 19.68M (-464.7%)
|
11.28M
est: 19.68M (-42.7%)
|
13.65M
est: 25.76M (-47.0%)
|
92.73M
est: 41.22M (+125.0%)
|
46.37M
46.37M – 46.37M
+12.5% YoY
|
| SGA |
243.14M
est: 177.46M (+37.0%)
|
243.52M
est: 157.29M (+54.8%)
|
201.59M
est: 178.09M (+13.2%)
|
226.17M
est: 193.22M (+17.1%)
|
319.51M
est: 251.85M (+26.9%)
|
345.85M
est: 319.62M (+8.2%)
|
371.94M
est.
|
363.60M
est: 457.99M (-20.6%)
|
298.78M
est: 273.91M (+9.1%)
|
296.25M
est: 273.91M (+8.2%)
|
332.21M
est: 359.09M (-7.5%)
|
222.43M
est: 466.21M (-52.3%)
|
554.31M
554.31M – 554.31M
+18.9% YoY
|
| EPS |
0.07
est: 0.23 (-67.7%)
|
0.03
est: 0.03 (-0.1%)
|
0.24
est: 0.25 (-2.7%)
|
0.30
est: 0.28 (+7.1%)
|
0.70
est: 0.38 (+84.2%)
|
0.36
est: 0.42 (-14.3%)
|
0.46
est.
|
0.26
est: 0.57 (-54.4%)
|
-0.15
est: 0.04 (-475.0%)
|
0.02
est: 0.04 (-50.0%)
|
0.03
est: 0.05 (-40.0%)
|
0.18
est: 0.08 (+125.0%)
|
0.09
0.09 – 0.09
+12.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
204.09M
OE per share TTM
0.38
Owner's Yield
4.43%
Maintenance CapEx ratio
39.25%
Maint CapEx / Avg PPE
89.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 10 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.9K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 11.1K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 548.0K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 880.74 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.7K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.4K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 628.30 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 72.57 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 23.85 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 11.36 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
67.4K
Shares Outstanding
581.69M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gen Chang Zheng | Chief Engineer & Employee Representative Member of Supervisory Board | — | male |
| Li Zong | Deputy GM & Director | — | female |
| Ni Zeng | Deputy GM, Chief Financial Officer, Accounting Supervisor & Non-Independent Director | — | female |
| Sen Li | Executive Vice President & Chief Operating Officer | — | male |
| Xiasi Kuang | Deputy General Manager | — | female |
| Xu Wang | Chairman & GM | — | male |
| Zehui Shao | Deputy GM, Secretary of the Board of Directors & Non-Independent Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300016.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
